TREG101

**TREG101** is an investigational immune-tolerance candidate from Treg Therapeutics based on the company's TILAC platform, short for Tolerance Induction via Linked Adjuvant/Cytokine conjugate. Public descriptions characterize it as a covalently linked conjugate of an adjuvant and an anti-inflammatory cytokine intended to condition dendritic-cell signaling toward a tolerogenic state, promote regulatory immune responses, and restore immune balance in autoimmune disease rather than broadly suppress immunity. The identities of its individual molecular components, molecular targets, dosage form, route, and disease-specific clinical program have not been publicly disclosed in concrete primary sources reviewed. ([biobase.whitefordresearch.com](https://biobase.whitefordresearch.com/companies/tregtherapeutics))